Triple-Negative Breast Cancer: Tumor Immunogenicity and Beyond

Overview

Journal Int J Breast Cancer

Publisher Wiley

Date 2024 Oct 14

PMID 39399414

Authors

Elio Ibrahim

Ernest Diab

Rony Hayek

Karim Hoyek

Hampig Kourie

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is a breast malignancy with a poor prognosis and limited therapeutic options. Many studies show that TNBC exhibits heterogeneity across clinical, histopathological, and molecular levels. In this review, we discuss the immunogenic features of TNBC with a focus on immunotherapy and the current standard of care in the neoadjuvant, adjuvant, and metastatic setting. In addition, we address the ongoing research on immunotherapy, antibody-drug conjugates (ADCs), poly ADP-ribose polymerase (PARP) inhibitors, and future challenges in the treatment of this entity.

References

Cochrane D, Bernales S, Jacobsen B, Cittelly D, Howe E, DAmato N . Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014; 16(1):R7. PMC: 3978822. DOI: 10.1186/bcr3599. View

Thike A, Yong-Zheng Chong L, Cheok P, Li H, Yip G, Bay B . Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol. 2013; 27(3):352-60. DOI: 10.1038/modpathol.2013.145. View

Abdel-Latif M, Youness R . Why natural killer cells in triple negative breast cancer?. World J Clin Oncol. 2020; 11(7):464-476. PMC: 7407924. DOI: 10.5306/wjco.v11.i7.464. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Burstein H, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P . Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019; 30(10):1541-1557. DOI: 10.1093/annonc/mdz235. View

Yeong J, Lim J, Lee B, Li H, Chia N, Ong C . High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. Front Immunol. 2018; 9:1209. PMC: 5988856. DOI: 10.3389/fimmu.2018.01209. View

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K . Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2017; 19(1):40-50. DOI: 10.1016/S1470-2045(17)30904-X. View

Lee J, Yost S, Yuan Y . Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. Cancers (Basel). 2020; 12(6). PMC: 7352772. DOI: 10.3390/cancers12061404. View

Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning W . PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol. 2017; 22(6):1026-1033. DOI: 10.1007/s10147-017-1161-7. View

10.

Bonzanini M, Morelli L, Bonandini E, Leonardi E, Pertile R, Dalla Palma P . Cytologic features of triple-negative breast carcinoma. Cancer Cytopathol. 2012; 120(6):401-9. DOI: 10.1002/cncy.21207. View

11.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

12.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

13.

Roesler A, Malasi S, Koslosky L, Hartmayer P, Naab T, Carter J . PDJ amplicon in triple negative breast cancer. Sci Rep. 2023; 13(1):618. PMC: 9837184. DOI: 10.1038/s41598-023-27887-8. View

14.

Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32(27):2959-66. PMC: 4162494. DOI: 10.1200/JCO.2013.55.0491. View

15.

Kala C, Athar M, Kala S, Khan L, Jauhari R, Satsangi A . Clinical and Cyto-Morphological Characterization of Triple Negative Breast Cancer. J Cytol. 2019; 36(2):84-88. PMC: 6425775. DOI: 10.4103/JOC.JOC_47_18. View

16.

Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler R . Germline Mutations in Triple-Negative Breast Cancer. Breast Care (Basel). 2017; 12(1):15-19. PMC: 5465748. DOI: 10.1159/000455999. View

17.

Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

18.

Jardim D, Goodman A, Gagliato D, Kurzrock R . The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2020; 39(2):154-173. PMC: 7878292. DOI: 10.1016/j.ccell.2020.10.001. View

19.

Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J . Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022; 33(11):1149-1158. DOI: 10.1016/j.annonc.2022.07.1940. View

20.

Cortes J, Rugo H, Cescon D, Im S, Yusof M, Gallardo C . Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022; 387(3):217-226. DOI: 10.1056/NEJMoa2202809. View